Saturday 17 October 2026
Export ACHV’s income statement to Excel — free account
Achieve Life Sciences, Inc.
ACHV Healthcare Biotechnology
In the quarter to June 2026, EPS fell 116.2%, free cash flow fell 19.0% and total debt rose 63.9%, each against the same quarter a year earlier.
6.38
0.59
−8.46%
Follow ACHV
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | — | — | — | 0.00 |
P/S ratio |
— | — | — | — | — | — | — | — | — | 0.01 |
P/FCF ratio |
— | — | — | — | — | — | — | — | — | 0.00 |
P/Operating CF |
— | — | — | — | — | — | — | — | — | (1.81) |
P/B ratio |
— | — | — | — | — | — | — | — | — | 0.18 |
Price to Tangible BV |
— | — | — | — | — | — | — | — | — | 0.00 |
EV/Sales |
— | — | — | — | — | — | — | — | — | 0.06 |
EV/EBITDA |
— | — | — | — | — | — | — | — | — | 0.28 |
EV/Operating CF |
— | — | — | — | — | — | — | — | — | (4.92) |
EV/FCF |
— | — | — | — | — | — | — | — | — | (1.85) |
Quick Ratio |
4.01 | 5.14 | 0.75 | 1.15 | 9.49 | 12.22 | 5.81 | 4.47 | 2.74 | 0.17 |
Current Ratio |
4.39 | 5.46 | 0.82 | 1.27 | 9.80 | 12.60 | 6.04 | 4.75 | 2.93 | 0.01 |
Net Debt/EBITDA |
0.36 | 0.63 | (0.04) | 0.21 | 0.85 | 2.46 | 1.00 | 1.16 | 0.86 | (0.55) |
Debt/Assets |
39.51% | 25.78% | 86.37% | 54.05% | 31.55% | 0.42% | 1.72% | 0.12% | 0.27% | 21.78% |
Debt/Equity |
0.77 | 0.48 | (11.55) | 1.95 | 0.53 | 0.00 | 0.02 | 0.00 | 0.00 | 1.36 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.91 | 0.75 | 0.82 | 0.89 | 0.89 | 0.91 | 0.93 | 0.84 | 0.86 | 0.16 |
Capex/Depreciation |
(0.01) | 0.00 | (0.09) | 0.00 | 0.00 | (0.07) | (0.21) | (0.13) | 0.00 | 0.00 |
Interest Coverage |
(67.01) | (17.92) | (9.55) | (22.81) | (1,946.71) | (213.77) | (97.22) | (74.93) | (315.81) | (8.44) |
| (257.67%) | (409.51%) | (869.88%) | (233.04%) | (101.49%) | (53.24%) | (96.86%) | (107.15%) | (249.33%) | (6.49%) | |
| (135.90%) | (137.33%) | (120.85%) | (109.31%) | (75.51%) | (48.00%) | (81.64%) | (87.57%) | (154.51%) | (3.98%) | |
ROIC |
(2,109.47%) | 0.00% | 0.00% | 0.00% | (159,105.77%) | (575.45%) | (590.96%) | (655.87%) | (172.71%) | (75.23%) |
Return on Tangible Assets |
(177.39%) | (133.71%) | 778.26% | (738.96%) | (82.79%) | (43.27%) | (112.90%) | (103.13%) | (267.65%) | 44.12% |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.04 | 0.05 | 0.12 | 0.08 | 0.06 | 0.07 | 0.15 | 0.18 | 0.36 | 1.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | — | — | — | — | — | — | (28.33) |
Graham Number |
— | — | — | — | — | — | — | — | — | 0.00 |
Earnings Yield |
— | — | — | — | — | — | — | — | — | (330.91%) |
Free Cash Flow Yield |
— | — | — | — | — | — | — | — | — | (479.50%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.13) | (0.93) | (1.23) | (3.55) | (3.63) | (4.96) | (36.93) | (60.53) | (379.46) | (2,020.00) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | (0.13) | (0.21) | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.13) | (0.93) | (1.24) | (3.55) | (3.63) | (4.96) | (37.06) | (60.73) | (379.46) | (2,020.00) |
Cash per Share |
0.84 | 1.07 | 0.78 | 2.34 | 5.30 | 13.19 | 40.45 | 83.21 | 229.42 | 150.00 |
Shareholders Equity per Share |
0.49 | 0.65 | (0.07) | 0.78 | 3.45 | 13.71 | 43.81 | 90.04 | 328.29 | 6,100.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Book value per Share |
0.49 | 0.65 | (0.07) | 0.78 | 3.45 | 13.71 | 43.81 | 90.04 | 328.29 | 6,100.00 |
Free Cash Flow |
(49.47) | (29.77) | (24.50) | (37.57) | (29.44) | (13.49) | (15.27) | (10.66) | (9.11) | (0.20) |
Working Capital |
30.81 | 29.79 | (3.83) | 5.73 | 40.04 | 34.04 | 14.47 | 12.27 | 3.90 | (3.05) |
Capital Expenditures |
0.00 | — | (0.02) | — | — | (0.02) | (0.05) | (0.04) | — | (0.05) |
Net Current Asset Value |
19.62 | 18.73 | (3.84) | 5.66 | 25.12 | 33.96 | 14.31 | 12.26 | 3.90 | (3.18) |
EV/EBIT |
— | — | — | — | — | — | — | — | — | 0.00 |
Capex to Sales |
0.00 | — | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
Price to Operating Income |
— | — | — | — | — | — | — | — | — | 0.03 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.46 | 8.06 | 4.78 | 0.86 |
Cash ROIC |
(66.46%) | (45.65%) | (79.47%) | (76.25%) | (34.21%) | (18.40%) | (43.53%) | (35.03%) | (67.90%) | (13.89%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
— | — | 0.11 | 0.13 | 0.08 | — | 0.01 | 0.01 | 0.26 | 0.32 |
Average Payables |
1.41 | 1.28 | 1.14 | 1.25 | 0.59 | 0.60 | 0.50 | 0.18 | 0.15 | 0.72 |
Average Assets |
40.21 | 29.00 | 24.67 | 38.74 | 43.91 | 30.69 | 20.08 | 14.49 | 6.85 | 31.01 |
Average Common Equity |
21.21 | 9.73 | 3.43 | 18.17 | 32.66 | 27.67 | 16.93 | 11.84 | 4.24 | 19.03 |
Columns are period end dates